HK1130688A1 - Useful combinations of monobactam antibiotics with beta-lactamase inhibitors - Google Patents

Useful combinations of monobactam antibiotics with beta-lactamase inhibitors

Info

Publication number
HK1130688A1
HK1130688A1 HK09108949.6A HK09108949A HK1130688A1 HK 1130688 A1 HK1130688 A1 HK 1130688A1 HK 09108949 A HK09108949 A HK 09108949A HK 1130688 A1 HK1130688 A1 HK 1130688A1
Authority
HK
Hong Kong
Prior art keywords
beta
lactamase inhibitors
useful combinations
formula
monobactam antibiotics
Prior art date
Application number
HK09108949.6A
Other languages
English (en)
Inventor
Eric Desarbre
Berangere Gaucher
Malcolm G P Page
Patrick Roussel
Original Assignee
Basilea Pharmaceutica Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Basilea Pharmaceutica Ag filed Critical Basilea Pharmaceutica Ag
Publication of HK1130688A1 publication Critical patent/HK1130688A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/429Thiazoles condensed with heterocyclic ring systems
    • A61K31/43Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4436Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47Quinolines; Isoquinolines
    • A61K31/472Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/662Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/69Boron compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pyrrole Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
HK09108949.6A 2005-12-07 2009-09-28 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors HK1130688A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP05026699 2005-12-07
EP06006291 2006-03-27
PCT/CH2006/000685 WO2007065288A2 (en) 2005-12-07 2006-12-07 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors

Publications (1)

Publication Number Publication Date
HK1130688A1 true HK1130688A1 (en) 2010-01-08

Family

ID=37964638

Family Applications (2)

Application Number Title Priority Date Filing Date
HK09108949.6A HK1130688A1 (en) 2005-12-07 2009-09-28 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
HK13107938.5A HK1180597A1 (en) 2005-12-07 2013-07-08 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors --

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK13107938.5A HK1180597A1 (en) 2005-12-07 2013-07-08 Useful combinations of monobactam antibiotics with beta-lactamase inhibitors --

Country Status (21)

Country Link
US (3) US8901293B2 (xx)
EP (3) EP1965798B1 (xx)
JP (1) JP5180836B2 (xx)
KR (2) KR101403164B1 (xx)
CN (3) CN103724330B (xx)
AT (1) ATE529111T1 (xx)
AU (2) AU2006322564B2 (xx)
BR (1) BRPI0619552A2 (xx)
CA (2) CA2783572C (xx)
CY (2) CY1112160T1 (xx)
DK (3) DK1965798T3 (xx)
ES (3) ES2373461T3 (xx)
HK (2) HK1130688A1 (xx)
HR (1) HRP20110841T1 (xx)
MX (1) MX338505B (xx)
PL (2) PL2308874T3 (xx)
PT (2) PT2308874E (xx)
RS (1) RS52068B (xx)
SI (1) SI1965798T1 (xx)
WO (1) WO2007065288A2 (xx)
ZA (1) ZA200804306B (xx)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2007300531A1 (en) * 2006-09-27 2008-04-03 Merck Sharp & Dohme Corp. Novel inhibitors of beta-lactamase
NZ579375A (en) * 2007-03-23 2012-02-24 Basilea Pharmaceutica Ag Combination medicaments for treating bacterial infections
DK2197881T3 (da) * 2007-09-17 2013-06-24 Basilea Pharmaceutica Ag Fremgangsmåde til fremstillingen af brokoblede monolactam-mellemprodukter
EP2209474A4 (en) 2007-10-09 2013-07-24 Sopharmia Inc BROAD SPECTRUM BETA-LACTAMASE INHIBITORS
BRPI0819983A2 (pt) * 2007-12-04 2015-06-16 Basilea Pharmaceutica Ag Processo para a preparação de derivados de ácido 2-(amino primário/secundário)hidrocarbil)carbamoil-7-oxo-2, 6-diaza-biciclo-[3.2.0]-heptano-6-sulfônico
DK2666774T3 (en) * 2008-01-18 2015-03-23 Merck Sharp & Dohme Beta-lactamase INHIBITORS
KR20110095856A (ko) 2008-12-01 2011-08-25 글레이드 올가닉스 프라이비트 리미티드 아즈트레오남과 카르바페넴류인 메로페넴 및 에르타페넴의 상승작용적 조합
EP2593434A1 (en) 2010-07-16 2013-05-22 Purdue Pharma LP Pyridine compounds as sodium channel blockers
BR112013003045B1 (pt) 2010-08-10 2021-08-31 Rempex Pharmaceuticals, Inc. Composto e respectivo uso, composição farmacêutica, recipiente estéril e método para preparar composição farmacêutica para administração
ES2542431T3 (es) 2010-11-29 2015-08-05 Pfizer Inc Monobactamas
US9012491B2 (en) 2011-08-31 2015-04-21 Rempex Pharmaceuticals, Inc. Heterocyclic boronic acid ester derivatives and therapeutic uses thereof
UY34585A (es) 2012-01-24 2013-09-02 Aicuris Gmbh & Co Kg Compuestos b-lactámicos sustituidos con amidina, su preparación y uso
WO2013136170A1 (en) 2012-03-16 2013-09-19 Purdue Pharma L.P. Substituted pyridines as sodium channel blockers
US9156858B2 (en) 2012-05-23 2015-10-13 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10561675B2 (en) 2012-06-06 2020-02-18 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20140128364A1 (en) * 2012-11-05 2014-05-08 Rempex Pharmaceuticals Therapeutic uses of tigemonam and carumonam
US9422314B2 (en) 2012-12-07 2016-08-23 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2014096941A1 (en) 2012-12-20 2014-06-26 Purdue Pharma L.P. Cyclic sulfonamides as sodium channel blockers
CN103435650B (zh) * 2012-12-28 2015-12-02 南京海融医药科技有限公司 单环β-内酰胺类化合物、制备方法及其制药用途
CN104994844A (zh) 2013-01-04 2015-10-21 莱姆派克斯制药公司 硼酸衍生物及其治疗用途
US9132140B2 (en) 2013-01-04 2015-09-15 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9101638B2 (en) 2013-01-04 2015-08-11 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US9241947B2 (en) 2013-01-04 2016-01-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
ES2730013T3 (es) 2013-01-10 2019-11-07 Venatorx Pharmaceuticals Inc Inhibidores de betalactamasa
WO2014151958A1 (en) 2013-03-14 2014-09-25 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CN103554112B (zh) * 2013-11-07 2016-04-13 中国科学院昆明植物研究所 顺式稠环的β-内酰胺化合物的合成方法
CN103823014B (zh) * 2014-02-12 2017-03-29 长春大合生物技术开发有限公司 组合物、试剂盒及其用途和用其分析氨基酸方法
US10730866B2 (en) 2014-04-07 2020-08-04 Purdue Pharma L.P. Indole derivatives and use thereof
EP4356736A2 (en) 2014-05-05 2024-04-24 Melinta Therapeutics, Inc. Synthesis of boronate salts
EP3139930A4 (en) 2014-05-05 2018-01-17 Rempex Pharmaceuticals, Inc. Salts and polymorphs of cyclic boronic acid ester derivatives and therapeutic uses thereof
CA2947041A1 (en) 2014-05-19 2015-11-26 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
RU2686740C2 (ru) 2014-06-11 2019-04-30 Венаторкс Фармасьютикалс, Инк. Ингибиторы бета-лактамазы
US9511142B2 (en) 2014-06-11 2016-12-06 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
CA2952968A1 (en) 2014-07-01 2016-01-07 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
WO2016081297A1 (en) 2014-11-18 2016-05-26 Rempex Pharmaceuticals, Inc. Cyclic boronic acid ester derivatives and therapeutic uses thereof
US20180051041A1 (en) 2015-03-17 2018-02-22 Rempex Pharmaceuticals, Inc. Boronic acid derivatives and therapeutic uses thereof
US10399996B2 (en) 2015-09-11 2019-09-03 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
WO2017100537A1 (en) 2015-12-10 2017-06-15 VenatoRx Pharmaceuticals, Inc. Beta-lactamase inhibitors
KR20180093925A (ko) 2015-12-15 2018-08-22 머크 샤프 앤드 돔 코포레이션 박테리아 감염을 치료하기 위한 비아릴 모노박탐 화합물 및 그의 사용 방법
MA43811A (fr) 2016-03-07 2018-11-28 Merck Sharp & Dohme Composés d'arylmonobactame bicycliques et leurs méthodes d'utilisation pour le traitement des infections bactériennes
ES2894251T3 (es) 2016-06-30 2022-02-14 Qpex Biopharma Inc Derivados de ácido borónico y usos terapéuticos de los mismos
CN107641119B (zh) * 2016-07-21 2019-11-08 中国科学院上海药物研究所 单环β-内酰胺-铁载体轭合物及其制备方法和用途
US10889600B2 (en) 2016-08-04 2021-01-12 VenatoRx Pharmaceuticals, Inc. Boron-containing compounds
BR112019012994A2 (pt) 2016-12-21 2019-12-03 Aicuris Gmbh & Co Kg terapia de combinação com compostos de b-lactama de amidina substituída e inibidores de b-lactamase para infecções com cepas bacterianas resistentes a antibiótico
US11267826B2 (en) 2017-05-26 2022-03-08 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
WO2018218190A1 (en) 2017-05-26 2018-11-29 VenatoRx Pharmaceuticals, Inc. Penicillin-binding protein inhibitors
KR102425959B1 (ko) * 2017-10-02 2022-07-27 머크 샤프 앤드 돔 코포레이션 박테리아 감염의 치료를 위한 크로만 모노박탐 화합물
IL273551B2 (en) 2017-10-11 2024-02-01 Qpex Biopharma Inc Boronic acid derivatives and their synthesis
EP3747883A4 (en) 2018-01-29 2020-12-16 Medshine Discovery Inc. B-LACTAM MONOCYCLIC COMPOUND FOR TREATMENT OF BACTERIAL INFECTION
JP7179185B2 (ja) 2018-12-18 2022-11-28 メッドシャイン ディスカバリー インコーポレイテッド 医薬の製造おける単環式β-ラクタム化合物の使用
EP4046998B1 (en) 2019-11-22 2024-02-28 Suzhou Erye Pharmaceutical Co., Ltd. Sulfonylurea ring substituted monocyclic beta-lactam antibiotics
EP4079305A4 (en) 2019-12-19 2024-01-10 Shenzhen Optimum Biological Tech Co Ltd APPLICATION OF A COMPOUND IN THE PREPARATION OF DRUG
CN113754651B (zh) * 2020-06-02 2023-04-18 中国医学科学院医药生物技术研究所 一种β-内酰胺化合物、其用途及其制备方法
CN111675641B (zh) * 2020-06-04 2023-09-08 宁夏农林科学院农业资源与环境研究所(宁夏土壤与植物营养重点实验室) 单环β-内酰胺类化合物、单环内酰胺类化合物盐及其制备方法
WO2023091438A1 (en) 2021-11-18 2023-05-25 Merck Sharp & Dohme Llc Chromane amidine monobactam antibiotics
WO2023250467A2 (en) * 2022-06-24 2023-12-28 Baylor College Of Medicine Inhibitors of antimicrobial resistance and methods using same
CN115304594B (zh) * 2022-10-12 2023-02-14 苏州二叶制药有限公司 磺酰脲环取代的化合物的盐型及其晶型

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ177159A (en) * 1974-04-20 1978-03-06 Beecham Group Ltd Clavulanic acid, salts, esters and preparation thereof from streptomyces clavuligerus: pharmaceutical compositions
US4348518A (en) 1974-05-05 1982-09-07 Hoffmann-La Roche Inc. Cephalosporins
FR2278335A1 (fr) 1974-07-04 1976-02-13 Fujisawa Pharmaceutical Co Derives d'azetidinones et leurs procedes de preparation
GB1570278A (en) * 1975-10-06 1980-06-25 Fujisawa Pharmaceutical Co O-substituted-2-azetidinone derivatives and the preparation thereof
ES467601A1 (es) 1977-03-12 1979-06-16 Hoechst Ag Procedimiento para la preparacion de derivados de cefem.
IT1192287B (it) * 1977-11-14 1988-03-31 Fujisawa Pharmaceutical Co Derivati di acido cefalosporanico ad azione farmaceutica e relativo procedimento di preparazione
JPS6339237B2 (xx) 1979-04-06 1988-08-04 Karuruberugu Baiotekunorojii Ltd As
US4432970A (en) * 1979-11-23 1984-02-21 Pfizer Inc. 6-beta-Halopenicillanic acid 1,1-dioxides as beta-lactamase inhibitors
US4775670A (en) * 1980-09-29 1988-10-04 E. R. Squibb & Sons, Inc. 2-oxo-1-azetidinesulfonic acid salts
US4337197A (en) * 1980-10-31 1982-06-29 E. R. Squibb & Sons, Inc. O-sulfated β-lactam hydroxamic acids and intermediates
EP0055465B1 (en) 1980-12-31 1989-08-23 Fujisawa Pharmaceutical Co., Ltd. 7-acylaminocephalosporanic acid derivatives and processes for the preparation thereof
NZ199981A (en) * 1981-04-09 1985-08-16 Squibb & Sons Inc 2-oxo-1-(((substituted sulphonyl)amino)carbonyl)azetidines
US4572801A (en) * 1981-04-30 1986-02-25 Takeda Chemical Industries, Ltd. 4-Carbamoyloxymethyl-1-sulfo-2-oxoazetidine derivatives and their production
IT1211080B (it) 1981-07-21 1989-09-29 Craf Sud Idrazonocefem derivati biologicamente attivi.
US4499016A (en) * 1981-08-06 1985-02-12 E. R. Squibb & Sons, Inc. 2-Oxo-1-[(acylamino)sulfonyl]azetidines
US4394504A (en) 1981-10-07 1983-07-19 American Home Products Corporation Cephalosporin derivatives
DE3372768D1 (de) * 1982-06-03 1987-09-03 Hoffmann La Roche 1-sulfo-2-oxoazetidine derivatives
US4939253A (en) 1982-08-04 1990-07-03 E. R. Squibb & Sons, Inc. 2-oxoazetidin-1-yloxy acetic acids and analogs
JPS59141554A (ja) 1983-02-01 1984-08-14 Sogo Yatsukou Kk 新規錯体形成化合物及びそれを有効成分として含有する血圧降下剤
WO1985004876A1 (en) * 1984-04-24 1985-11-07 Takeda Chemical Industries, Ltd. 2-azetidinone derivatives and process for their preparation
EP0135194A1 (en) * 1983-09-16 1985-03-27 Takeda Chemical Industries, Ltd. Azetidinones and their production
US5137884A (en) * 1983-11-16 1992-08-11 Merck & Co., Inc. N-tetrazolyl beta-lactams
FI82471C (fi) * 1984-01-26 1991-03-11 Beecham Group Plc Foerfarande foer framstaellning av farmakologiskt aktiva 6-metylenpenemderivater.
US4826833A (en) * 1984-01-30 1989-05-02 Pfizer Inc. 6-(Substituted)methylene-penicillanic and 6-(substituted)hydroxymethylpenicillanic acids and derivatives thereof
US4638061A (en) * 1985-01-28 1987-01-20 E. R. Squibb & Sons, Inc. [3S(Z)]-2-[[[1-(2-amino-4-thiazolyl)-2-[[2,2-dimethyl-4-oxo-1-(sulfooxy)-3-azetidinyl]amino]-2-oxoethylidene]-amino]oxy] acetic acid and intermediate
CA1283404C (en) 1986-07-01 1991-04-23 Shigeru Sanai Cephalosporin compounds, processes for their preparation and antibacterial agents
US4891369A (en) * 1986-12-03 1990-01-02 Taiho Pharmaceutical Company, Limited 2β-Substituted-methylpenicillanic acid derivatives, and salts and esters thereof
DE68928174T2 (de) 1988-03-16 1997-12-18 Eisai Co Ltd Verfahren zur Herstellung von Cephemderivaten
ZA918014B (en) * 1990-11-05 1992-07-29 Squibb & Sons Inc Heteroaroyl derivatives of monocyclic beta-lactam antibiotics
IT225640Y1 (it) 1991-04-02 1997-01-13 Beltrame Ernesto Off Spa Dispositivo di supporto per posate
ES2090393T3 (es) * 1991-04-11 1996-10-16 Hoffmann La Roche Beta-lactamas.
EP0544307A1 (en) * 1991-11-27 1993-06-02 Banyu Pharmaceutical Co., Ltd. Alkylaminoakylpyrrolidinylthiocarbapenem derivatives
GB9202298D0 (en) * 1992-02-04 1992-03-18 Ici Plc Antibiotic compounds
TW383308B (en) 1993-08-24 2000-03-01 Hoffmann La Roche 2-beta-alkenyl penam sulfones as beta-lactamase inhibitors
AU2737295A (en) 1994-06-09 1996-01-04 Glaxo Group Limited Phenethanolamine derivatives and their use as atypical beta-adrenoceptor agonists
US5629306A (en) 1994-12-09 1997-05-13 Research Corporation Technologies, Inc. 7-alkylidene cephalosporanic acid derivatives and methods of using the same
US5686441A (en) * 1995-08-04 1997-11-11 Syphar Laboratories, Inc. Penam sulfones as β-lactamase inhibitors
US5888998A (en) * 1997-04-24 1999-03-30 Synphar Laboratories, Inc. 2-oxo-1-azetidine sulfonic acid derivatives as potent β-lactamase inhibitors
US5994340A (en) 1997-08-29 1999-11-30 Synphar Laboratories, Inc. Azetidinone derivatives as β-lactamase inhibitors
AU5546000A (en) 1999-06-14 2001-01-02 Protherics Molecular Design Limited Compounds
US6884791B2 (en) 1999-07-06 2005-04-26 Methylgene, Inc. Inhibitors of β-lactamase
US6921756B2 (en) * 1999-07-06 2005-07-26 Methylgene, Inc. Inhibitors of β-lactamase
WO2002001219A1 (en) 2000-06-29 2002-01-03 Peeze Binkhorst, Ignatius, Aloysius, Gerardus, Maria Method and apparatus for determination of the adhesion of layers of repair mortar to concrete constructions
FR2812635B1 (fr) 2000-08-01 2002-10-11 Aventis Pharma Sa Nouveaux composes heterocycliques, preparation et utilisation comme medicaments notamment comme anti- bacteriens
DE60111757T2 (de) 2000-09-14 2006-04-27 Pantherix Ltd. 3-(Heteroarylacetamido)-2-oxoazetidin-1-sulfonsäure-derivate als antibakterielle Mittel
FR2835186B1 (fr) * 2002-01-28 2006-10-20 Aventis Pharma Sa Nouveaux composes heterocycliques, actifs comme inhibiteurs de beta-lactamases
FR2848210B1 (fr) 2002-12-06 2007-10-19 Aventis Pharma Sa Nouveaux composes heterocycliques, leur preparation et leur utilisation comme medicaments, notamment comme anti-bacteriens et inhibiteurs de beta-lactamases
US7439253B2 (en) * 2002-12-06 2008-10-21 Novexel Heterocyclic compounds, their preparation and their use as medicaments, in particular as antibacterials and beta-lactamase inhibitors

Also Published As

Publication number Publication date
CN103724330A (zh) 2014-04-16
US9346799B2 (en) 2016-05-24
WO2007065288A2 (en) 2007-06-14
HRP20110841T1 (hr) 2012-01-31
CY1112160T1 (el) 2015-12-09
EP2308874A1 (en) 2011-04-13
AU2010246404B2 (en) 2012-06-28
CN102988362B (zh) 2014-11-05
EP2308874B1 (en) 2013-01-23
CN101410111B (zh) 2012-12-12
HK1180597A1 (en) 2013-10-25
AU2006322564A1 (en) 2007-06-14
PL2308874T3 (pl) 2013-06-28
AU2010246404A1 (en) 2010-12-16
CY1113939T1 (el) 2016-07-27
ATE529111T1 (de) 2011-11-15
KR101403164B1 (ko) 2014-06-03
WO2007065288A8 (en) 2008-08-14
CN102988362A (zh) 2013-03-27
CN101410111A (zh) 2009-04-15
SI1965798T1 (sl) 2012-01-31
US20160122320A1 (en) 2016-05-05
KR20130065742A (ko) 2013-06-19
CA2629570A1 (en) 2007-06-14
EP2484680A1 (en) 2012-08-08
PT2308874E (pt) 2013-04-26
CN103724330B (zh) 2015-08-19
CA2783572A1 (en) 2007-06-14
PL1965798T3 (pl) 2012-02-29
EP2484680B1 (en) 2013-06-26
JP2009518317A (ja) 2009-05-07
CA2783572C (en) 2016-08-09
ES2428824T3 (es) 2013-11-11
EP1965798B1 (en) 2011-10-19
US20100056478A1 (en) 2010-03-04
KR20080081165A (ko) 2008-09-08
WO2007065288A3 (en) 2008-06-05
EP1965798A2 (en) 2008-09-10
AU2006322564B2 (en) 2010-09-09
US8901293B2 (en) 2014-12-02
DK2484680T3 (da) 2013-09-08
JP5180836B2 (ja) 2013-04-10
BRPI0619552A2 (pt) 2011-10-04
RS52068B (en) 2012-06-30
US20150031662A1 (en) 2015-01-29
DK1965798T3 (da) 2011-11-28
ES2373461T3 (es) 2012-02-03
ZA200804306B (en) 2009-02-25
CA2629570C (en) 2012-11-27
ES2402882T3 (es) 2013-05-10
DK2308874T3 (da) 2013-04-15
KR101448553B1 (ko) 2014-10-13
MX338505B (es) 2016-04-20
PT1965798E (pt) 2011-12-22

Similar Documents

Publication Publication Date Title
HK1130688A1 (en) Useful combinations of monobactam antibiotics with beta-lactamase inhibitors
PT2231667E (pt) Inibidores de beta-lactamase
EP2687533A3 (en) Acrylamide derivatives as FAB I inhibitors
TW200734344A (en) Antibacterial agents
HK1121162A1 (en) Oxazole compound and pharmaceutical composition
BRPI0715936A2 (pt) a composiÇço dos antibiàticos que compreende antibiàticos beta-lactamicos e agentes quelantes iânicos.
BRPI0602150A (pt) composição antimicrobiana sinergìstica
EP2090577A8 (en) Heteroaryl compounds, compositions thereof, and their use as protein kinase inhibitors
WO2007067559A3 (en) Antibacterial agents
WO2006120563A3 (en) Antibacterial agents
CL2011000783A1 (es) Combinacion sinergica de un compuesto heterociclico nitrogenado de formula i antibacteriano con otro compuesto antibacteriano; medicamento; composicion farmaceutica; util para tratar infecciones bacterianas.
UA96759C2 (xx) ПОХІДНІ 2-АРИЛІНДОЛУ ЯК mPGES-1 ІНГІБІТОРИ$ПРОИЗВОДНЫЕ 2-АРИЛИНДОЛА КАК mPGES-1 ИНГИБИТОРЫ
CL2007003519A1 (es) Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
CL2007001542A1 (es) Compuestos derivados de aminotiazoles, composicion farmaceutica; y uso para el tratamiento de infecciones bacterianas.
CL2007003693A1 (es) Compuestos derivados de pirido [3,2-b] [1,4] tiazina; composicion farmaceutica que contiene dichos compuestos; y su uso en el tratamiento de infecciones bacterianas.
CL2007001910A1 (es) Compuestos derivados de penem; composicion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
WO2010036000A3 (en) Novel oxazolidinone derivatives with cyclic amidoxime or cyclic amidrazone and pharmaceutical compositions thereof
TW200800993A (en) Organic compounds
TW200727897A (en) Bicyclic 6-alkylidene-penem β-lactamase inhibitors and β-lactam antibiotic combination: a broad spectrum antibiotic
CL2008003688A1 (es) Compuesto derivado de aminotiazol macrociclico; composicion farmaceutica que lo comprende; y su uso para la preparacion de un medicamento util en el tratamiento de infecciones bacterianas.
BRPI0704121A (pt) composição antimicrobiana sinergìstica
WO2007027323A3 (en) TRICYCLIC 6-ALKYLIDENE-PENEM β-LACTAMASE INHIBITORS AND β-LACTAM ANTIBIOTIC COMBINATION: A BROAD SPECTRUM ANTIBIOTIC
CL2007003518A1 (es) Compuestos derivados de quinolina sustituida; proceso de preparacion; compuesto intermediario; composicion farmaceutica; combinacion farmaceutica; y uso en el tratamiento de una infeccion bacteriana.
MX2010014248A (es) Nuevos antibioticos de trinem e inhibidores de beta-lactamasas.
WO2008098396A3 (en) Oxazolidinones and their use as hypocholesterolemic agents

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161207